This newly discovered signaling pathway could be therapeutically exploited, since the subgroup of patients with DcR3 positive RCC might benefit from the inhibition of the drugable targets PI3K/AKT and NFATc1. This evidence concerns the gene TNFRSF6B and renal cell carcinoma.